<DOC>
	<DOCNO>NCT00555399</DOCNO>
	<brief_summary>The goal clinical research study learn vorinostat give isotretinoin temozolomide help control glioblastoma gliosarcoma . The safety drug combination also study .</brief_summary>
	<brief_title>Vorinostat , Isotretinoin Temozolomide Adults With Recurrent Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , randomly assign ( flip coin ) 1 3 group . If first 30 participant study , randomly assign group . If enrol first 30 participant , likely enrol group show good result . - If Group 1 , take vorinostat isotretinoin . - If Group 2 , take isotretinoin temozolomide . - If Group 3 , take vorinostat , isotretinoin temozolomide . Study Drug Administration : Each study cycle 28 day . You take vorinostat mouth day Days 1-7 Days 15-21 cycle . You take vorinostat mouth morning , time day . Vorinostat capsule swallow whole open . If capsule damage broken , spill powder vorinostat capsule clean carefully . If come contact powder , wash hand thoroughly . If spill surface , area must wash least 3 time rub alcohol , follow water . Vorinostat capsule store room temperature ( 59°-86°F [ 15°-30°C ] ) dry area . You take vorinostat food , high fat meal . You also take isotretinoin mouth 2 time day Days 1-21 cycle . You take temozolomide mouth day Days 1-7 Days 15-21 cycle . You take temozolomide mouth bedtime , time day . You swallow temozolomide capsule whole , one right , without chew . They take empty stomach ( least 2 hour eat ) 1 cup ( 8 ounce ) water . If vomit take vorinostat , isotretinoin and/or temozolomide , `` make '' dose . You wait next schedule dose . Study Visits : At Week 2 every cycle : ° Blood ( 1 teaspoon ) draw routine test . At Week 4 Cycles 1 : - Blood ( 2 teaspoon ) draw routine test check well blood clot , . - If able become pregnant , blood ( 1/2 teaspoon ) pregnancy test . At Week 4 Cycle 2 every cycle ( Cycles 4 , 6 , 8 , ) : - You physical exam , include neurological exam . - Blood ( 2 teaspoon ) collect routine test . This routine blood draw also include pregnancy test become pregnant . - Blood ( 2 teaspoon ) drawn check well blood clot , pancreas function amount fat blood . - You brain MRI scan check status disease . At time study , extra test may perform doctor think need safety . The study doctor tell extra test . Length Study : You may take study drug ( ) 1 year . You may continue receive study drug ( ) beyond 1 year doctor decide best interest . You take study early disease get bad intolerable side effect . Long-Term Follow-Up : After last dose study drug , every 2 month , may call ask feeling . This phone call take 5-10 minute . If stop study drug intolerable side effect , visit clinic every 2 month , unless disease get bad . At visit , You physical exam , include neurological exam . - Blood ( 2 teaspoon ) collect routine test . This routine blood draw also include pregnancy test become pregnant . - Blood ( 2 teaspoon ) drawn check well blood clot , pancreas function amount fat blood . - You brain MRI scan check status disease . This investigational study . Isotretinoin , temozolomide , vorinostat FDA approve drug commercially available . The use drug combination investigational . Up 135 patient take part study . Up 30 enrol MD Anderson .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>1 . Patients histologically proven supratentorial WHO grade IV glioma ( glioblastoma gliosarcoma ) eligible study . 2 . Patients must show unequivocal evidence tumor recurrence progression MRI scan fail radiation therapy . The scan do prior study entry document progression review treat physician document change tumor dimension confirm recurrence . Patients prior therapy include interstitial brachytherapy stereotactic radiosurgery must confirmation true progressive disease rather radiation necrosis . 3 . ( 2. continue ) Patients prior therapy include interstitial brachytherapy , Gliadel wafers stereotactic radiosurgical procedure must confirmation true progressive disease rather radiation necrosis . Such confirmation may use advanced imaging study ( e.g . PET scan , diffusionperfusion MRI , SPECT etc ) available , surgical sample histological confirmation ( surgery require ) . 4 . Patients may 2 prior relapse . 5 . All patient must sign IRB approve informed consent indicate awareness investigational nature study . Patients must sign authorization release protect health information . 6 . The baseline onstudy MRI perform within 14 day ( + 3 work day ) prior registration steroid dosage stable decrease least 5 day . If steroid dose increase date imaging initiation therapy ( time ) , new baseline MRI require . The type scan , i.e. , MRI , must use throughout period protocol treatment tumor measurement . 7 . Patients undergone recent resection recurrent progressive tumor eligible long recovered effect surgery . Evaluable measurable disease follow resection recurrent tumor mandate eligibility study . To best assess extent residual measurable disease postoperatively , MRI do later 96 hour immediate postoperative period 46 week postoperatively . 8 . Patients must 18 year old old . 9 . Patients must Karnofsky performance status equal great 60 . 10 . Patients must recover toxic effect prior therapy &lt; grade 2 non hematological grade 2 less hematological toxicity per CTC ver 4 ( except deep vein thrombosis ) : 4 week prior cytotoxic therapy and/or least two week vincristine , 6 week nitrosoureas , 3 week procarbazine administration , 1 week noncytotoxic agent , e.g. , interferon , tamoxifen , cisretinoic acid , etc . ( radiosensitizer count ) . Patients receive anticancer agent nontherapeutic purpose unrelated study 11 . ( 10. continue ) ( presurgically obtain pharmacology data agent ) eligible enter study provide recover toxic effect agent . Any question relate definition noncytotoxic agent direct Study Chair . 12 . Patients must adequate bone marrow function ( ANC = &gt; 1,500/mm^3 platelet count = &gt; 100,000/mm^3 ) , adequate liver function ( SGPT = &lt; 3 time upper limit normal alkaline phosphatase = &lt; 2 time upper limit normal , bilirubin = &lt; 1.5 mg/dl ) , adequate renal function ( BUN creatinine = &lt; 1.5 time upper limit normal ) normal serum amylase lipase prior start therapy . Elevated cholesterol triglycerides contraindication study enrollment , manage clinically appropriate treat physician . 13 . Patients must willing able comply FDA mandate iPLEDGE program treatment isotretinoin ( cRA ) . Patients must sign specific informed consent treatment cRA , mandate iPLEDGE guideline . Women childbearing potential must pregnant , must breastfeed must practice adequate contraception one month participation study . Male Female patient treatment vorinostat must agree use adequate method contraception duration study , 30 day last dose study medication . 14 . Prior treatment dose dense regimens temozolomide allow ( e.g , 7 day on/7 day , 21 day/28 day daily low dose continuous dose ) . However , prior treatment standard day 15 dosing adjuvant set low dose daily dose part chemoradiation therapy allow 15 . Prior treatment isotretinoin allow trial base hypothesis HDAC inhibition potentially overcome resistance retinoids . 1 . Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix bladder ) , unless complete remission therapy disease minimum 3 year . 2 . Patients must : ) active infection ; b ) disease obscure toxicity dangerously alter drug metabolism , especially liver disease ; c ) serious intercurrent medical illness ; ) prior treatment HDAC inhibitor . However , patient receive anticancer agent nontherapeutic purpose ( eg. , part pharmacology study without therapeutic intent ) remain eligible enrollment study . 3 . Prior treatment bevacizumab allow . 4 . Patients receive valproic acid ( VPA ) , anticonvulsant drug HDAC inhibitor property , exclude , unless switch alternative agent prior treatment initiation . No wash period require . 5 . Patients previous treatment carboplatin . 6 . Patients know allergy component vorinostat , know allergy temozolomide and/or isotretinoin . 7 . Patient must able tolerate procedure require study include periodic blood sampling , study related assessment , management treat institution duration study . Inability comply protocol study procedure ( example , inability swallow tablet ) exclusion criterion . 8 . Patients receive treatment antiepileptic medication exclude . Vorinostat metabolize cytochrome P450 3A4 ( CYP 3A4 ) . However , vorinostat may potentially suppress CYP 3A4 activity . Therefore , patient preferably treat nonenzyme induce antiepileptic medication avoid potential interaction vorinostat . 9 . ( 8. continue ) However , use nonenzyme induce antiepileptic medication mandatory . If enzymeinducing antiepileptic drug use , monitor drug level consider , consider clinically appropriate treat physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Anaplastic Glioma</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>SAHA</keyword>
	<keyword>MSK-390</keyword>
	<keyword>Zolinza</keyword>
	<keyword>Isotretinoin</keyword>
	<keyword>Accutane</keyword>
	<keyword>13-cis-Retinoic Acid</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>CBT</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
</DOC>